A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemiaSimon He, Andrew W. Roberts, Samantha J. Busfield et al.|Leukemia & lymphoma/Leukemia and lymphoma|2014Cited by 126
Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemiaHervé Dombret, Hagop M. Kantarjian, Simon Durrant et al.|Leukemia & lymphoma/Leukemia and lymphoma|2019Cited by 64